Neurology® Podcast

Dr. Luca Bartolini discusses autoimmune encephalitis and the role of antibody testing based on a Practice Current survey run between November 2017 and May 2018.

Dr. Jeffrey Ratliff talks with Dr. Anneleen Berende about her paper on the effect of prolonged antibiotic treatment on cognitive performance in patients with Lyme borreliosis. Dr. Andrew Southerland focuses his interview with Dr. Stephen Klasko on hospitals of the future, following a panel at the World Economic Forum in Davos, Switzerland. The article can be found here: https://www.statnews.com/2019/01/26/dispatch-from-davos-future-hospitals/.

This month's Delayed Recall highlights episodes on autoimmune neurology. A segment from October 23, 2018 finds Dr. Stacey Clardy talking to Dr. Andrew McKeon about his paper on paraneoplastic neuronal intermediate filament autoimmunity. This episode concludes with an interview on a Neurology: Neuroimmunology & Neuroinflammation paper on IgLON5 autoimmunity between Dr. Stacey Clardy and Dr. Andrew McKeon from March 27, 2018.

In the first segment, Dr. James Grogan talks with Dr. David Llewellyn about his Neurology: Clinical Practice paper on predictors of dementia misclassification when using brief cognitive assessments. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Rob M.A. de Bie on a randomized delayed-start trial of Levodopa in Parkinson's Disease, published in the New England Journal of Medicine. The article can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa1809983.

1. A multicentre comparison of MOG-IgG cell based assays. 2. [What's Trending]: the DEFUSE 3 study. In the first segment, Dr. Stacey Clardy talks with Dr. Paddy Waters about his paper on a multicentre comparison of MOG-IgG cell based assays. In the second part of the podcast, Dr. Andrew Southerland focuses his interview with Dr. Adam de Havenon on the DEFUSE 3 study. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1. The prevalence of MS in the United States: A population-based estimate using health claims data. 2. [What's Trending]: Neurology on the Hill and advocacy issue. In the first segment, Dr. Stacey Clardy talks with Dr. Mitch Wallin about his paper examining a population-based estimate on the prevalence of MS in the United States. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Johnson on Neurology on the Hill and advocacy issues. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1. Quality Improvement in Neurology: Universal Neurology Quality Measurement Set Executive Summary2. [What's Trending]: The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come. In the first segment, Dr. Stacey Clardy talks with Dr. Wayne Anderson and Dr. Justin Martello about their paper on quality improvement in neurology. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Nick Watts on health and climate change shaping the health of nations for centuries to come. DISCLOSURES: Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wayne Anderson reports no disclosures. Dr. Justin Martello has received travel funding or speaker honoraria from 1) Teva, cash, (2) Abbvie, cash, (3) Lundbeck, cash and is a member of the AAN's Quality and Safety Subcommittee. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

1.Physical activity, common brain pathologies, and cognition in community-dwelling older adults 2. [What's Trending]: Deep space medicine. In the first segment, Dr. Jeff Burns talks with Dr. Aron Buchman about his paper on physical activity, common brain pathologies, and cognition in community-dwelling older adults. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Alejandro Rabinstein on the medicine of deep space. Dr. Jeff Burns has served on the DSMB for three NIH-funded trials; has received honorarium and travel for speaking at an Astra-Zeneca symposium; has served on the editorial board of Journal of Alzheimer's Disease; has served as a consultant for protocol development for Stage 2 Innovations; has received commercial research support from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, vTv Therapeutics, Janssen, and Roche and for investigator-initiated studies from Eli Lilly and Astra-Zeneca; has received governmental research support from the National Institutes of Health; and has provided expert witness testimony in legal cases. Dr. Aron Buchman has received government research support from the National Institutes of Health. Dr. Jason Crowell reports no disclosures. Dr. Alejandro Rabinstein has served as a member of the external committee for adverse event adjudication for PREVAIL trial/CAP2 registry; has served on the editorial boards of Neurology, Neurocritical Care, Stroke, CONTINUUM , and UpToDate; and has received publishing royalties from Elsevier and Oxford.

1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What's Trending]: 'Landmark study' shows brain cells revamp their DNA, perhaps sparking Alzheimer's disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study' showing brain cells revamp their DNA, perhaps sparking Alzheimer's disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.

1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program 2. [What's Trending]: Mapping Symptoms to Brain Networks with the Human Connectome. In the first segment, Dr. Teshamae Monteith talks with Dr. Roy Hamilton about his paper on reducing neurodisparity. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Michael D. Fox on mapping symptoms to brain networks with the human connectome.DISCLOSURES Dr. Teshamae Monteith has served on Scientific Advisory Boards for Lilly, Supernus, Teva, Electrocore, Promius and is an editorial advisory board member for Neurology. Dr. Roy Hamilton has served without compensation on the scientific advisory board for an NIH-funded R21 project titled ""Combining tDCS and neurorehabilitation to treat age-related deficits of mobility and cognition (UPfront Walking Study) as the data safety monitor. Dr. Hamilton has served on editorial boards for (1)Cognitive and Behavioral Neurology, editorial board member, and (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present. Dr. Hamilton is employed by Neuronix LTD as a Medical consultant, 2014 to present. Dr. Hamilton has done consultancies for Geurbet Ltd. on the development of an FDA-mandated clinical trial and received approximately $6000 for work in the last 2 years (2017-18). Dr. Hamilton received research support from 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 . 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) Templeton Foundation/Imagination Institute Principal Investigator 7/01/2015 – 6/30/2017 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018. Dr. Hamilton's legal proceedings include Kline & Specter Attorneys at Law, Consultant, 2014, 2015. Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Michael D. Fox has patents issues or submitted using brain imaging to guide brain stimulation. Dr. Fox has done consultancies for Mint Labs and has received research support from one government entity (1) NIH, K23NS083741 and research support from two foundations and societies (1) Dystonia Medical Research Foundation (2) National Parkinson's Foundation.